ImageneBio (IMA) hands CEO new multi-year stock grants
Rhea-AI Filing Summary
ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received equity awards on August 14, 2026. She was granted 254,800 shares of Common Stock in the form of restricted stock units, which begin vesting on April 14, 2027 and continue in quarterly installments, subject to continued service. She was also granted two employee stock option awards covering 137,200 shares and 250,000 shares of Common Stock at an exercise price of $5.84 per share, each vesting over four years under specified monthly schedules. Following the RSU grant, she directly owned 493,705 Common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 254,800 shares
Net Buy
3 txns
Insider
Yarema Kristin
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F2 | 137,200 | $0.00 | $0.00 |
| Grant/Award | Employee Stock Option (Right to Buy) F3 | 250,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 254,800 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 387,200 shares (Direct);
Common Stock — 493,705 shares (Direct)
Footnotes (3)
- F1. Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
- F2. The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
- F3. The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
Key Figures
RSU-based Common Stock granted: 254800 shares
Stock options granted (first award): 137200 shares
Stock options granted (second award): 250000 shares
+5 more
8 metrics
RSU-based Common Stock granted
254800 shares
Restricted stock units granted to CEO on August 14, 2026
Stock options granted (first award)
137200 shares
Employee Stock Option grant on August 14, 2026
Stock options granted (second award)
250000 shares
Employee Stock Option grant on August 14, 2026
Option exercise price
$5.84 per share
Exercise price for both option grants
Options expiration date
August 13, 2036
Expiration date for both option grants
CEO Common Stock holdings after grant
493705 shares
Directly owned Common Stock after RSU grant
RSU initial vesting date
April 14, 2027
25% of RSUs vest and settle on this date
Monthly vesting installments (F3 options)
48 installments
Number of monthly vesting tranches starting May 14, 2026
Key Terms
Restricted stock units, Employee Stock Option, exercise price, vesting
4 terms
Restricted stock units financial
"Represents the number of shares of the Issuer's Common Stock underlying restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Employee Stock Option financial
"Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"conversion_or_exercise_price": "5.8400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The options vest over four years, with 25% of the shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did ImageneBio (IMA) grant to CEO Kristin Yarema?
On August 14, 2026, ImageneBio granted CEO Kristin Yarema 254,800 RSU-based Common shares and stock options over 387,200 shares at $5.84 per share, all subject to multi‑year vesting and continued service.
How do the new RSUs for ImageneBio (IMA) CEO vest?
The 254,800 RSUs for ImageneBio’s CEO vest with 25% settling into Common Stock on April 14, 2027, and the remaining RSUs vesting in 12 equal quarterly installments, contingent on continued service.
How do the 250,000 stock options granted to ImageneBio (IMA) CEO vest?
The 250,000 stock options vest over four years in 48 equal monthly installments starting on May 14, 2026, provided the CEO remains in continuous service through each vesting date.
What is the exercise price and expiration date of the new ImageneBio (IMA) CEO options?
Both new option grants to ImageneBio’s CEO have an exercise price of $5.84 per share and expire on August 13, 2036, giving a roughly ten‑year term from the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
